Leerink analyst David Larsen lowered his price target for AmerisourceBergen to $91 from $105 as he is "incrementally" more cautious on the drug distribution group. Distributors have downside protection for generic deflation, but it is for products in inventory, the analyst tells investors in a research note, adding that the lower priced products that start flowing through the channel will result in lower gross profit dollars once the inventory is worked through. Despite the headwinds, Larsen sees the company positioned to deliver above market growth for the foreseeable future and reiterates an Outperform rating on the shares.